Direkt zum Inhalt
Merck
Alle Fotos(1)

Key Documents

View All Documentation

Y0000119

Hydroxycarbamid

European Pharmacopoeia (EP) Reference Standard

Synonym(e):

Hydroxyharnstoff, Hydroxycarbamid

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Lineare Formel:
NH2CONHOH
CAS-Nummer:
127-07-1
Molekulargewicht:
76.05
Beilstein:
1741548
MDL-Nummer:
MFCD00007943
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329830855
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

hydroxycarbamide

Hersteller/Markenname

EDQM

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

Lagertemp.

2-8°C

SMILES String

NC(=O)NO

InChI

1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)

InChIKey

VSNHCAURESNICA-UHFFFAOYSA-N

Angaben zum Gen

human ... RRM1(6240) , RRM2(6241) , RRM2B(50484)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

Hydroxycarbamide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem./physiol. Wirkung

Anti-neoplastisch. Inaktiviert die Ribonukleosid-Reduktase durch Bildung eines freien Nitroxid-Radikals, das ein freies Tyrosyl-Radikal im aktiven Zentrum des Enzyms bindet. Dadurch wird die Synthese von Desoxynukleotiden blockiert, was die DNA-Synthese hemmt und die Synchronisation oder den Zelltod in der S-Phase induziert.

Verpackung

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Sonstige Hinweise

Sales restrictions may apply.

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

Piktogramme

Health hazard
GHS08

Signalwort

Danger

H-Sätze

H340,H361

Gefahreneinstufungen

Muta. 1B - Repr. 2

Lagerklassenschlüssel

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Leider sind derzeit keine COAs für dieses Produkt online verfügbar.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

A Tefferi et al.
Leukemia, 28(12), 2300-2303 (2014-05-06)
The impact of calreticulin (CALR) mutations on long-term survival in essential thrombocythemia (ET) was examined in 299 patients whose diagnosis predated 2006. Mutational frequencies were 53% for Janus kinase 2 (JAK2), 32% for CALR and 3% for MPL; the remaining
Patrick T McGann et al.
Current opinion in hematology, 18(3), 158-165 (2011-03-05)
Sickle cell anemia (SCA) is a well characterized severe hematological disorder with substantial morbidity and early mortality. Hydroxyurea is a potent inducer of fetal hemoglobin, and evidence over the past 25 years has documented its laboratory and clinical efficacy for
Alessandro M Vannucchi et al.
The New England journal of medicine, 372(5), 426-435 (2015-01-30)
Ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, was shown to have a clinical benefit in patients with polycythemia vera in a phase 2 study. We conducted a phase 3 open-label study to evaluate the efficacy and safety of
John J Strouse et al.
Pediatrics, 122(6), 1332-1342 (2008-12-03)
Hydroxyurea is the only approved medication for the treatment of sickle cell disease in adults; there are no approved drugs for children. Our goal was to synthesize the published literature on the efficacy, effectiveness, and toxicity of hydroxyurea in children
John J Strouse et al.
Pediatric blood & cancer, 59(2), 365-371 (2012-04-21)
Hydroxyurea is the only approved medication in the United States for the treatment of sickle cell anemia (HbSS) and is widely used in children despite an indication limited to adults. We review the evidence of efficacy and safety in children
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.